Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus

Executive Summary

After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.

You may also be interested in...

UK NICE Changes Mind On Ocrevus After Roche Drops Price

Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.

Roche Wants More Flexibility For UK’s NICE To Consider Indication-Based Pricing

Roche is calling for HTA body NICE to have greater flexibility on indication-based pricing.

Indication-Based Pricing Hurdle A Block For Roche's Ocrevus In UK

The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts